Session Information
-
WCLC 2022
2022 World Conference on Lung Cancer
Conference Program for 2022 the World Conference on Lung Cancer
Presentation Date(s):- August 6 - 9, 2022
- Total Presentations: 2137
All times listed are in Vienna, Austria Time, CEST (UTC+2:00)
PL - Plenary
IBS - Interactive Breakfast Session (in-person attendees only)
ES - Education Session
OA - Oral Session
MA - Mini Oral Session
P - Posters
EP - ePosters
WS - Workshops
LA – Lectureship Awards
IS - Industry Symposium
August 5 Fri
Aug 5 Saturday
August 6 Sat
Aug 6 Sunday
August 7 Sun
Aug 7 Monday
August 8 Mon
Aug 8 Tuesday
August 9 Tue
Aug 9
-
+
OA03 - Molecular Targeted Treatments
- 14:30 - 15:40
- 8/07/2022
- Location: Hall C7
- Not for CME Credit
- Type: Oral
- Track: Metastatic Non-small Cell Lung Cancer - Molecular Targeted Treatments
- Moderators:Andrew Ciupek, David R. Gandara
-
+
OA03.05 - Tepotinib in Patients with MET Exon 14 (METex14) Skipping NSCLC: Primary Analysis of the Confirmatory VISION Cohort C
14:52 - 15:02 | Presenter: Michael Thomas
- Abstract
Loading...
-
+
EP08.02 - Metastatic Non-small Cell Lung Cancer - Molecular Targeted Treatments
- 09:45 - 18:00
- 8/07/2022
- Location: Exhibit Hall - Hall B
- Not for CME Credit
- Type: E-Poster
- Track: Metastatic Non-small Cell Lung Cancer - Molecular Targeted Treatments
-
+
EP08.02-162 - Tepotinib with an EGFR-Tyrosine Kinase Inhibitor (TKI) in Patients with EGFR-mutant MET-amplified NSCLC: A Case Series
Presenter: Xiuning Le- Abstract
Loading...
-
+
EP11.01 - Pathology - Genomics & Analytics
- 09:45 - 18:00
- 8/07/2022
- Location: Exhibit Hall - Hall B
- Not for CME Credit
- Type: E-Poster
- Track: Pathology - Genomics & Analytics
-
+
EP11.01-005 - Ultra-Fast Gene Fusion Assessment as a Reflex Testing in Daily Clinical Practice for Advanced Non-small Cell Lung Cancer Patients
Presenter: Paul Hofman- Abstract
Loading...
-
+
OA12 - Novel and Combination Strategies for SCLC
- 16:00 - 17:00
- 8/08/2022
- Location: Hall C8
- Not for CME Credit
- Type: Oral
- Track: Small Cell Lung Cancer and Neuro-Endocrine Tumors
- Moderators:Alessandra Curioni-Fontecedro, Kostas Syrigos
-
+
OA12.06 - First-Line Pembrolizumab or Placebo Combined With Etoposide and Platinum for ES-SCLC: KEYNOTE-604 Long-Term Follow-Up Results
16:32 - 16:42 | Presenter: Charles M Rudin
- Abstract
Loading...
